Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Arrowhead Pharma (NQ: ARWR )

36.05 +1.38 (+3.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 942,438
Open 35.49
Bid (Size) 35.11 (2)
Ask (Size) 36.50 (2)
Prev. Close 34.67
Today's Range 34.56 - 36.07
52wk Range 23.09 - 48.48
Shares Outstanding 105,736,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-6.39%
-6.39%
1 Month
-12.88%
-12.88%
3 Month
+17.08%
+17.08%
6 Month
+13.29%
+13.29%
1 Year
+9.37%
+9.37%

More News

Read More
Arrowhead CEO Christopher Anzalone Addresses The 'Really Important Event' In Lung Disease
Via Investor's Business Daily
Where Arrowhead Pharma Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for Arrowhead Pharma
Via Benzinga
Is Arrowhead Pharmaceuticals a Buy Now?
Via The Motley Fool
Expert Ratings for Arrowhead Pharma
Via Benzinga
What Arrowhead Pharmaceutical's Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder
Via Benzinga
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
Via Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
Via The Motley Fool
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars
Via Benzinga
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Making Surprising Moves in Thursday Session
Via Investor Brand Network
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
Via Benzinga
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Highlighted for Surprising Price Action
Via Investor Brand Network
Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.